Next Article in Journal
Correction: Sainz et al. Analysis of Thioredoxins and Glutaredoxins in Soybean: Evidence of Translational Regulation under Water Restriction. Antioxidants 2022, 11, 1622
Next Article in Special Issue
Thermal Stability and Antioxidant Activity of Bioactive Compounds in Bread Enriched with Bee Pollen and Bee Bread
Previous Article in Journal
Topical Absorption of Glutathione–Cyclodextrin Nanoparticle Complex in Healthy Human Subjects Improves Immune Response against Mycobacterium avium Infection
Previous Article in Special Issue
Nutritional Improvements of Sourdough Breads Made with Freeze-Dried Functional Adjuncts Based on Probiotic Lactiplantibacillus plantarum subsp. plantarum and Pomegranate Juice
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

How Healthy Is It to Fortify Cocoa-Based Products with Cocoa Flavanols? A Comprehensive Review

by
Marta Palma-Morales
1,2,
Sonia Melgar-Locatelli
3,4,
Estela Castilla-Ortega
3,4 and
Celia Rodríguez-Pérez
1,2,5,*
1
Biomedical Research Centre, Institute of Nutrition and Food Technology (INYTA) ‘José Mataix’, University of Granada, Avda. del Conocimiento s/n, 18071 Granada, Spain
2
Department of Nutrition and Food Science, Faculty of Pharmacy, University of Granada, Cartuja Campus, 18011 Granada, Spain
3
Biomedical Research Instute of Malaga and Platform in Nanomedicine-IBIMA Platform BIONAND, 29590 Málaga, Spain
4
Departament of Psychobiology and Methodology of Behavioural Sciences, Faculty of Psychology, University of Malaga, 29010 Málaga, Spain
5
Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain
*
Author to whom correspondence should be addressed.
Antioxidants 2023, 12(7), 1376; https://doi.org/10.3390/antiox12071376
Submission received: 5 June 2023 / Revised: 28 June 2023 / Accepted: 29 June 2023 / Published: 3 July 2023

Abstract

:
(1) Background: Cocoa’s healthy benefits may be attributed to the potent antioxidant activity of cocoa polyphenols, mainly flavanols, which have been characterised as existing in a high concentration in cocoa. However, the phenolic composition of cocoa and cocoa-derived products is highly variable, and manufacturing processes might significantly reduce their phenolic content. For that reason, the full characterisation of cocoa and cocoa-derived products before evaluating their bioactivity is crucial. The aim of this review is to analyse the available evidence on the effect of flavanol-fortified cocoa-derived products on human health. (2) Methods: Forty-eight clinical trials focused on the health effect of consuming flavanol-fortified drinks, bars and chocolate have been reviewed, with a total of 1523 subjects. (3) Results: Although studies differ widely in methodology, dosage, duration, and target population, beneficial effects of flavanol-rich cocoa consumption have been observed at doses ranging from 45.3 mg/d to 1078 mg/d, especially on cardiovascular health and cognitive function. (4) Conclusions: Considering the high consumption and acceptability of cocoa and cocoa-derived products, the fortification of cocoa products as well as other highly consumed foods with cocoa flavanols could be an effective strategy for health promotion.

1. Introduction

Cocoa is extracted from cocoa beans that are the fatty seeds of the Theobroma cacao tree. For consumption, the Theobroma cacao beans are processed as a paste (‘cocoa liquor’) containing non-fat cocoa solids and cocoa butter. ‘Cocoa powder’ results from eliminating cocoa butter from the liquor. In contrast, ‘chocolate’ combines cocoa liquor with additional cocoa butter and sugar; it is frequently enhanced with other components such as nuts or milk [1]. In Europe, the average per capita chocolate consumption reached 5 kg per year in 2022, and it is expected to grow at an average annual rate of around 4.8% between 2022 and 2027 [2]. Cocoa is rich in phenolic compounds (PCs), with the highest content of these being present in pure cocoa powder, followed by baking chocolate and dark chocolate; the lowest polyphenol content is found in so-called “white chocolate”, which is made from the cocoa butter [3,4].
PCs are considered essential in our diet. They are classified into various groups according to their chemical structure, with phenolic acids and flavonoids being the most abundant phenolic compounds in diet. Numerous studies have evaluated their effects on human health, attributing to them an important role in protecting the organism against external stimuli and in the elimination of reactive oxygen species [5]. PCs are synthetised by plants under normal and stress conditions and have various functions such as attracting insects for pollination and protecting against pathogens and ultraviolet radiation [6]. Thus, these compounds are present in foods such as tea, cocoa, fruits, vegetables, and honey, and their content varies widely depending on the variety, plant origin, agronomic and storage conditions, harvesting time, and climate, among other factors [7]. Improvements in lipid profiles, blood pressure, insulin resistance and systemic inflammation have been observed following consumption of PCs-rich foods, and these improvements are associated with improved cardiovascular health. In the central nervous system, these compounds counteract chronic and acute inflammatory processes, possess neuroprotective activity, and effectively reduce some signs and symptoms of neurodegenerative conditions, thus contributing to maintaining good brain health and overall quality of life [5].
The long-recognized health benefits of cocoa may be attributed to the potent antioxidant activity of cocoa polyphenols, mainly flavanols, which are found in cocoa in a higher concentration (460–610 mg/kg of flavanol monomers; 4–5 g/kg of flavanol polymers) than in other plant-derived foods such as beans, apricots, blackberries, apples, and tea leaves [8]. The main flavonoids contained in cocoa are flavan-3-ols and their oligomers and polymers (procyanidins). In addition, cocoa contains flavonoids such as epicatechin, quercetin and isoquercetin; flavones such as luteolin and apigenin; flavanones such as naringenin; anthocyanins and phenolic acids (Figure 1). These compounds are highly related to antioxidant activity [9]. Specifically, cocoa flavanols benefit the cardiovascular system, have anti-inflammatory properties, reduce insulin resistance and enhance the growth of beneficial gut microbiota [1,3,10,11]. In addition, cocoa consumption has numerous health benefits that potentiate cognitive function, although the actions of cocoa on the nervous system have scarcely been investigated [12]. Since 2014, it has been possible to claim that ‘cocoa flavanols help maintain the elasticity of blood vessels, which contributes to normal blood flow’ [13]. Nevertheless, it is important to note that the phenolic composition of cocoa and cocoa-derived products is highly variable, and their contents in foods can be influenced by factors such as the genotype of the cocoa plant (Forastero/Amazónico, Criollo or Trinitario), the region, the method of cultivation, and the manufacturing processes (fermentation, drying, roasting, and particularly alkalizing, which decreases the phenolic content) [11,14,15]. According to other published studies, the decrease in phenolic compounds is 2–4 g/100 g dry weight, as raw cocoa nibs contain 6–8 g/100 g dry weight and cocoa powder contains 4 g/100 g dry weight [16]. In addition, the roasting process results in the epimerisation of (−)-epicatechin to (−)-catechin, and the epimerisation of (+)-catechin to (−)-catechin, and alkalinization also increases the levels of (−)-catechin, which is absorbed more poorly than the (+)-enantiomer. Therefore, both cocoa and chocolate contain mainly (−)-epicatechin and a large amount of (−)-catechin (which is less fully absorbed), while the concentration of (+)-catechin is very low in contrast to raw cocoa beans [16].
In view of the above, the objective of this work is to review the effects of consuming cocoa-based products fortified in cocoa flavanol on human health, in order to determine whether their manufacture may be advisable for health promotion.

2. Materials and Methods

The US National Library of Medicine National Institutes of Health (PubMed) was used to search the literature from 2000 to 2023, in order to gain an overview of all the available evidence of the effect of cocoa flavanol-fortified products on human health. The following search equation strategy was used: “flavanol-rich cocoa” [All Fields] OR “flavonoid-rich cocoa” [All Fields] OR “high-flavanol cocoa” [All Fields]. Medical subject heading (MeSH) terms were included to increase the power of the search.
The main criteria of PICO (population, intervention, comparison, outcome) were followed to frame and answer the related clinical question. In this regard, the population included humans, the intervention was consumption of high-flavanol cocoa products, the comparison was made vs. low-flavanol cocoa products or placebo, and the outcomes were antioxidant effects, effects on cardiovascular health, visual function, cognitive function, and fatigability.
The inclusion criteria were the following: (1) clinical trials; (2) studies with cocoa or cocoa-derived products with a high flavanol content; (3) studies written in English. The exclusion criteria were (1) review articles; (2) studies written in languages other than English; (3) studies in animals; (4) studies without full access; (5) studies with the dose not made available; (6) studies with flavanol extracts; and (7) studies with combined treatments. Once the articles were selected based on reading the title, abstract and full text, and the results were classified according to the different health effects attributed to products enriched with cocoa flavanols, i.e., their effects on physical endurance and oxidative stress, cardiovascular risk factors, visual and cognitive function, and other effects in both healthy subjects and subjects with disease. These data have been summarised in different tables throughout the text, and a narrative review of the main outcomes has also been included.

3. Results

Forty-eight published articles were analysed, including a total of 1523 subjects with a mean age of 45.1 ± 16.6 years. Of the 1523 subjects, at least 762 were women (one study did not specify). The studies included different population groups (healthy subjects, subjects with renal disease, overweight or obese subjects, diabetic subjects, subjects with chronic heart failure, subjects with coronary artery disease, subjects with hypercholesterolaemia or hypertension, subjects with Parkinson’s disease, and subjects with multiple sclerosis), and included three different types of cocoa products: high-flavanol (HF) drinks, bars, and chocolate.

3.1. Effects in Healthy Subjects

Table 1 shows the effects of HF cocoa on exercise performance and oxidative stress in healthy subjects. A study conducted with 44 male endurance athletes reported a significant increase from baseline in the plasma ratio of follistatin/myostatin by modifying the levels of follistatin. Follistatin promotes adipose tissue browning and decreases body fat levels, and counteracts the myostatin blockade of muscle growth, making it an indicator of improved muscle function. Moreover, a decrease in body fat after 10 weeks of flavanol-rich cocoa consumption (425 mg flavanols/day) was observed. However, this may have led to a decrease in leptin levels (the hormone secreted by adipose tissue that sends the satiety signal to the brain, promotes lipolysis and depresses lipogenesis) [17]. In contrast, Patel et al. [18] observed no effects on exercise performance after a single dose of a chocolate bar containing from 88 to 1060 mg of flavanols in a study involving 15 healthy subjects aged 30 years on average. On the other hand, consumption of HF cocoa containing 425 mg of flavanols for 10 weeks reduced oxidative stress in a study with 56 male endurance athletes; however, no effects on aerobic capacity or exercise performance were observed [19]. Another study with 20 healthy men also reported a significant decrease in oxidative stress after a single dose of an HF cocoa drink (containing 187 mg of flavanols) compared to a control drink (14 mg of flavanols) [20]. Similarly, the study developed by Zhu et al. in 2005 showed a significant reduction in the susceptibility of erythrocytes to free radical-induced haemolysis, after consumption of 12.5–25 mg flavanols/kg body weight contained in cocoa beverages, compared to baseline [21].
Table 2 shows the effects of HF cocoa consumption by healthy individuals on cardiovascular risk factors. In a study conducted in middle-aged and elderly people (55–90 years), a significant improvement in several cardiovascular risk factors was observed, including a reduction in blood glucose and plasma triglycerides, as well as an increase in high-density lipoprotein (HDL) levels, physical performance, skeletal mass index, and quality of life after 12 weeks of consumption of an HF cocoa drink compared to placebo [22]. Similarly, consumption of flavanol-rich soluble cocoa for 4 weeks significantly increased HDL levels in healthy and moderately hypercholesterolemic subjects compared to milk consumption; however, a significant decrease in IL-10 from baseline was also observed [23].
A single dose of a chocolate bar containing 520 mg of flavanols significantly reduced pulse pressure, systolic blood pressure (SBP) and diastolic blood pressure (DBP) and attenuated the increase in pulse wave velocity in healthy sleep-deprived subjects (25.3 ± 3.6 years), as well as increased flow-mediated dilatation (FMD) and improved working memory accuracy compared to a flavanol-poor chocolate bar [24]. Likewise, a single dose of an HF cocoa drink significantly increased plasma levels of flavanols and FMD in healthy women (329 mg of flavanols) [25] and smokers (176–185 mg of flavanols) [26] compared to low-flavanol (LF) drinks. Brachial artery FMD also increased significantly from baseline after one week of consumption of an HF (918 mg) cocoa drink by male smokers aged 27 years [27]. Another study carried out in African Americans and Caucasian Americans showed a significant improvement in microvascular function and nitric oxide (NO) bioavailability, only in African Americans subjects, after a single dose of a cocoa drink containing 247.2 mg of flavanols [28]. A single dose of an HF cocoa drink (897 mg of flavanols) also showed platelet-modulating effects by reducing epinephrine-stimulated platelet activation and function from baseline, although to a lesser extent than aspirin, in healthy subjects from 22 to 49 years of age [29].
Chronic consumption of HF cocoa has also been shown to affect vascular function. Brachial artery FMD and plasma epicatechin significantly increased in a study conducted in healthy subjects after 2 weeks of consuming an HF chocolate bar [30]. Consumption of a cocoa beverage containing 821 mg of flavanols for 5 days increased FMD after hyperaemia in 48-year-old subjects [31], and increased NO-dependent vasodilation to ischaemia in healthy 44-year-old subjects [32]. However, it had no effects on blood pressure (BP). Consumption of HF (750 mg) dark chocolate for 8 weeks also had no effect on BP in prehypertensive healthy subjects (52.6 ± 12.6 years) [33].
Table 2. Effects on cardiovascular risk factors in healthy subjects.
Table 2. Effects on cardiovascular risk factors in healthy subjects.
DoseDurationSubjectsEffectsRef
HF (563 mg) or LF (38 mg) cocoa drinkSingle dose10 healthy and physically active men
22.6 ± 0.3 years
↑** blood glucose pre-exercise [34]
HF (179 mg), non-flavanol containing cocoa drink or placebo12 weeks61 healthy, middle-aged and elderly subjects (13 males, 48 females)
75.9 ± 5.8 years
↓** glycaemia
↓** TG
↑** HDL
↑** physical performance
↑** skeletal mass index
↑** quality of life
[22]
HF soluble cocoa (45.3 mg) or milk4 weeks24 healthy (11 males, 13 females) and 20 moderately hypercholesterolemic (9 males, 11 females) subjects
28 ± 8 years
↑** HDL
↑* dietary carbohydrate, protein and fibre intake
↓* IL-10
[23]
HF (520 mg) or LF (88.5 mg) chocolate bar
Cross-over
Single dose32 healthy sleep-deprived subjects (16 males, 16 females)
25.3 ± 3.6 years
↓** pulse pressure, SBP and DBP
↑** FMD
↓** increase in pulse wave velocity
↑** working memory accuracy
[24]
HF (329 mg) or LF (27 mg) cocoa drinkSingle dose10 healthy women
18–65 years
↑** FMD and oxygen saturation
↑** plasma epicatechin
[25]
HF (176–185 mg) or LF (<11 mg) cocoa drink
Cross-over
Single dose11 smokers (6 males, 5 females)
31 ± 1 years
↑** plasma levels of flavanols
↑** plasma levels of NO
↑** FMD
[26]
HF (918 mg) cocoa drink 1 week6 male smokers
27 ± 1 years
↑* flow-mediated dilation of brachial artery[27]
HF (247.2 mg/d) cocoa drink or non-flavanol containing drink
Cross-over
Single dose7 African American and 7 Caucasian American healthy subjects (8 males, 6 females)
22 ± 4 years
a microvascular function
a NO contribution
[28]
HF cocoa drink (897 mg) or aspirin (81 mg)Single dose16 healthy adults (8 males, 8 females)
22–49 years
↓* epinephrine-stimulated platelet activation and function[29]
HF (259 mg) or LF (47.6) chocolate bar2 weeks22 healthy subjects (11 males, 11 females)
32.2 ± 3.1 years
↑** brachial artery FMD
↑** plasma epicatechin
[30]
HF cocoa drink (821 mg)5 days34 healthy subjects (13 males, 21 females)
47.9 ± 3.0 years
↑* FMD after hyperaemia
↑ pulse wave amplitude
No effects on BP
[31]
HF (821 mg) cocoa drink or LF control drink5 days27 healthy subjects (11 males, 16 females)
44 ± 3.4 years
↑** pulse wave amplitude
↑** vasodilator response to ischaemia
No effects on BP
[32]
HF dark chocolate (750 mg), tomato extract capsule (15 mg lycopene), or placebo
Cross-over
8 weeks36 prehypertensive healthy subjects (19 males, 17 females)
52.6 ± 12.6 years
No effects on blood pressure[33]
↑ increase. ↓ decrease. * Significantly different from baseline. ** Significantly different from control. a Significantly different in African American subjects. HF: high-flavanol; MF: medium-flavanol; LF: low-flavanol; TG: triglycerides; HDL; high-density lipoproteins; SBP: systolic blood pressure; DBP: diastolic blood pressure; FMD: flow-mediated dilatation; NO: nitric oxide; BP: blood pressure.
Table 3 shows the effects of flavanol-rich cocoa on visual and cognitive functions. A study carried out on ten healthy physically active men showed that a single dose of an HF cocoa drink (563 mg flavanols) significantly increased pre-exercise blood glucose levels compared to a low-flavanol (LF) drink, which may have positive effects by improving executive function (effectively enhancing exercise-induced cognitive function improvement) [34]. Another study conducted in 18 healthy older adults (aged 50–65 years) reported a significant increase in cerebral blood flow after a single dose of an HF (494 mg) cocoa drink compared to an LF cocoa drink [35]. Similarly, the consumption of an HF (900 mg) cocoa drink for one week significantly increased cerebral blood flow from baseline in 34 healthy elderly subjects; however, there was no difference compared to the consumption of a cocoa drink low in flavanols [36]. Consumption of an HF cocoa drink for 5 days also significantly increased cerebral blood flow from baseline in young females (18–30 years), but there was no difference compared to an LF drink [37]. Another study carried out in elderly subjects (68.3 ± 3 years) reported a significant increase in serum brain-derived neurotrophic factor (BDNF) after the consumption of an HF cocoa drink (494 mg of flavanols) for 12 weeks compared to an LF cocoa drink, correlating with improvements in global cognitive performance [38]. These results are in line with those of Mastroiacovo et al. [39], who found that consumption of a cocoa drink containing 520–990 mg of flavanols for 8 weeks significantly improved cognitive function in elderly people (69.6 years). In a similar way, a single dose of dark chocolate containing 720 mg of flavanols significantly improved cognitive function in healthy young subjects compared to white chocolate. A significant improvement in visual function was also observed [40]. By contrast, no effects on retinal perfusion or subjective visual function were observed in another study in young people following a dose of dark chocolate containing 400 mg of flavanols [41], thus suggesting that 400 mg of flavanols is not enough to improve visual function. Another study conducted in young subjects (mean age 22.2 years) reported an improvement in spatial attention from baseline; however, no effect on temporal attention was found [42].
Table 4 shows the effects of cocoa with HF content on microbiota, UV-induced erythema, and in pregnant women. Consumption of an HF cocoa drink for 4 weeks significantly increased the populations of Bifidobacterial and Lactobacilli, and decreased that of Clostridia. In addition, a significant decrease in plasma triacylglycerol and C-reactive protein was observed [43].
Heinrich et al. [44] studied the effects of consuming a cocoa drink high in flavanols (326 mg) for 6 weeks on UV-induced erythema in healthy women. They observed a significant decrease in erythema and an increase in cutaneous and subcutaneous tissues’ blood flow, as well as in skin density and hydration. Similarly, Mogollon et al. [45] reported a significant increase in skin elasticity after 12 weeks of HF (200 mg) chocolate consumption; however, no effect on UV-induced erythema was observed.
Consumption of chocolate containing 400 mg of flavanols for 12 weeks by pregnant women significantly increased plasma theobromine levels compared to LF chocolate; however, no effects on FMD or BP were observed [46].

3.2. Subjects with Disease

The effects of HF cocoa in subjects with disease have also been studied (Table 5). Consumption of an HF (900 mg) cocoa drink for 4 weeks significantly increased FMD and decreased DBP in subjects with end-stage renal disease (mean age 65.5 ± 14 years); however, a significant increase in heart rate (HR) was also observed [47]. Several authors have studied the effects in overweight or obese subjects. A single dose of a cocoa drink containing 701 mg of flavanols significantly increased FMD and attenuated the exercise-induced increase in BP in subjects aged 54.9 ± 2.2 years [48]. Consumption of cocoa products high in flavanols for 4 weeks significantly increased both the basal and peak diameter of the brachial artery, the basal blood flow volume [49] and FMD [50], while also reducing the augmentation index (AIX) of the brachial artery (a measure of arterial stiffness), resulting in improved vasodilation [49,50]. In contrast, no effects on HOMA-IR or insulin-stimulated glucose disposal were observed after consumption of an HF (1218 mg) cocoa drink for 4 weeks by overweight or obese women aged 19–49 years [51]. A longer consumption (12 weeks) was tested in 23 subjects aged 44.9 ± 4.4 years, and showed a significant increase in FMD and a reduction in insulin resistance and DBP compared to an LF drink [52]. Similarly, consumption of HF cocoa drinks for 4 weeks by subjects with type II diabetes mellitus has been found to significantly increase FMD [53,54] and plasma levels of flavanol metabolites [54]. A significant reduction in DBP and the N-terminal pro-B-type natriuretic peptide (NT-proBNP) was also observed after 4 weeks of consumption of an HF (1064 mg) cocoa drink by subjects with chronic heart failure aged 70 ± 10 years, suggesting an improvement in cardiac function [55].
On the other hand, consumption of an HF (750 mg) cocoa drink for 4 weeks by subjects with coronary artery disease (64 ± 3 years) showed a significant improvement in endothelial function [56]; however, a lower dose (444 mg) for 6 weeks showed no effect in the same type of patients [57]. In a similar way, a study conducted in postmenopausal hypercholesterolemic women showed an improvement in endothelial function after consuming an HF (446 mg) cocoa drink for 6 weeks, as well as a significant increase in HDL levels [58]. Another study carried out with subjects with hypertension aged 56.6 ± 11.1 years reported that a single dose of an HF (712–1052 mg) cocoa drink significantly reduced SBP, DBP, and mean BP compared to an LF cocoa drink [59]. Two weeks of consuming an HF cocoa drink significantly increased insulin-stimulated changes in brachial artery diameter in hypertensive subjects (mean age 51 years); however, no effect on blood pressure was observed [60]. A significant decrease in HR was also observed after 6 weeks of consumption of HF chocolate in hypertensive men, as compared to LF chocolate [61].
On the other hand, a significant reduction in fatigability from baseline was observed in subjects with Parkinson’s disease and multiple sclerosis after one week [62] and eight weeks [63] of consuming an HF (194 mg) cocoa drink, respectively; however, no significant differences were observed compared to the consumption of an LF (18.36 mg) drink. Contrarily, no effect on fatigability measures was observed after a single dose of an HF (350 mg) cocoa drink in patients with multiple sclerosis [64], suggesting that a single dose is not enough to produce benefits.

4. Discussion

Many components of cocoa such as theobromine and minerals such as magnesium, copper, potassium, and calcium may benefit health. In this regard, some studies have highlighted the potential of theobromine as a protector against cancer, inflammation, and cardiovascular disease [65,66]. Dietary magnesium, copper, potassium and calcium can reduce the risk of hypertension and atherosclerosis [67]. For caffeine, both beneficial and harmful effects on several physiological systems have been described, but chocolate and cocoa are not primary sources of caffeine intake [68]. However, cocoa and dark chocolate’s long-recognized benefits for health have been attributed to the potent antioxidant activity of cocoa polyphenols (mainly flavanols).
Based on the results of the present review, it appears that chronic consumption of cocoa products with a high flavanol content in doses ranging from 45.3 mg/d to 1078 mg/d is more beneficial than a single dose. Beneficial effects, mainly on cardiovascular and cognitive function, have been observed, although positive effects on skin and microbiota have also been observed. Overall, there appear not to be significant differences in the reviewed effects between men and women, except in one study which reported a greater effect in women [46]. Regarding improvements in cognitive function, these have mainly been observed in older subjects [32,33,35,36]. Contrarily, no significant age-related differences in effects on cardiovascular health have been found. There also seems to be no difference in effect between healthy and diseased subjects.
Several reviews have highlighted some of the mechanisms of action of cocoa flavanols. Cocoa flavanols directly neutralize free radicals, reduce levels of reactive oxygen species, inhibit pro-oxidant enzymes and upregulate antioxidant defences [1,67]. In addition to their antioxidant actions, these compounds benefit the cardiovascular system by stimulating NO-mediated vasodilation (which results in reduced systemic blood pressure and increased arterial elasticity), have anti-inflammatory properties, reduce insulin resistance (thus lowering the circulating levels of glucose), and enhance the growth of beneficial gut microbiota [1,3,10,11]. In addition, NO acts in combination with BDNF to modulate neural progenitor cell growth and synaptic metabolism for the sustained adequacy of cognitive functions. Interestingly, NO release at the level of the thalamus contributes to the proper functioning of the neurovascular unit through increased blood flow and volume in the context of the brain. On the other hand, diets rich in bioactive compounds, such as polyphenols, induce adult hippocampal neurogenesis (AHN) by increasing synaptic plasticity and promoting long-term hippocampal potentiation, as well as enhancing learning and memory. In addition, they have been shown to increase the expression of two factors closely related to hippocampal neurogenesis: BDNF and the phosphorylated cyclic AMP-response element DNA-binding protein (pCREB) [69]. Cocoa flavanols may also exert beneficial effects through the inhibition of NADPH oxidase, thereby increasing NO levels [1]. Down-regulation of NF-κB and MAPK has also been observed after cocoa consumption, thus suggesting an inhibitory effect on the release of pro-inflammatory cytokines [70].
Unfortunately, the technological process related to the processing of cocoa beans for the manufacture of cocoa products affects the flavanol profile [9] in a qualitative and quantitative way. For instance, high temperatures and roasting times lead to the loss of bioactive compounds of interest, such as flavanols [71,72]. The preservation of polyphenols during cocoa manufacturing is known to be important for their beneficial effects on human health. Therefore, several studies have been carried out to develop procedures to reduce the loss of these compounds [73,74,75]. González-Barrio et al. [73] made a new formulation of dark chocolate that included 15% cocoa powder enriched with polyphenols; it had greatly increased antioxidant properties compared to conventional dark chocolate.
According to the studies included in the present review, for healthy subjects, the necessary daily dose of cocoa powder to reduce oxidative stress would be 4.45–10.63 g, to reduce cardiovascular risk factors, 1.13–22.95 g, and to improve cognitive function, 4.30–24.75 g. For subjects with metabolic disease, the dose needed to reduce cardiovascular risk factors would be 11.15–26.95 g of cocoa powder, and to reduce fatigue in people with Parkinson’s or multiple sclerosis, the dose would be 4.85–8.75 g of cocoa powder. In view of the aforementioned, and considering that one tablespoon of cocoa powder is equivalent to approximately 10 g, fortification with flavanols could be effective in order to enhance the beneficial effects of cocoa while maintaining a lower consumption amount. The dosage of other cocoa products (such as chocolate, cocoa bars or cocoa drinks) will depend on the percentage of cocoa they contain.
It should be noted that despite the promising positive effects of consumption of HF cocoa, more evidence (using the same dosage and trial protocols) is necessary to establish a real cause and effect relationship between HF cocoa intake and the described health benefits. In addition, due to the wide variation in the content of phenolic compounds in cocoa-derived products, it is essential to determine the concentration of these compounds in the foods used before conducting intervention studies.

5. Conclusions

A limited number of studies have been carried out so far. Together with a lack of standardized research and the variety of methodologies used, as well as differences in the duration of the interventions and doses used, the age of the subjects, and their physiological or pathological conditions, is difficult to draw comparisons between them. However, the beneficial effects of consuming cocoa rich in flavanols, especially on cardiovascular health and cognitive function, have been observed. Although the beneficial effects of cocoa have been demonstrated, it should be noted that some cocoa-derived products contain added sugars and additional fats that could have harmful effects, so consumption of such products should be occasional and moderate. It is also for this reason that the fortification of such products with cocoa flavanols could be effective in enhancing their beneficial effects whilst maintaining a lower level of consumption. It may also be appropriate to fortify other foods with cocoa flavanols so that the population can consume these compounds in greater quantities and benefit from their health effects.

Author Contributions

Conceptualization, M.P.-M. and C.R.-P.; methodology, M.P.-M.; validation, C.R.-P.; formal analysis, M.P.-M.; investigation, M.P.-M.; resources, M.P.-M.; data curation, C.R.-P.; writing—original draft preparation, M.P.-M.; writing—review and editing, S.M.-L., E.C.-O. and C.R.-P.; visualization, C.R.-P.; supervision, C.R.-P.; project administration, C.R.-P. and E.C.-O. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by Grant PID2020-114374RB-I00 funded by MCIN/AEI/10.13039/501100011033 (to C.R.-P. and E.C.-O.) and Junta de Andalucía-Consejería de Universidad, Investigación e Innovación—Proyect P21_00777.

Acknowledgments

Contract to the Junta de Andalucía-Consejería de Universidad, Investigación e Innovación Research Project: P21_00777 M.P.-M.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

AHNAdult hippocampal neurogenesis
AIXAugmentation index
BDNFBrain-derived neurotrophic factor
BPBlood pressure
DBPDiastolic blood pressure
FMDFlow-mediated dilatation
HFHigh-flavanol
LFLow-flavanol
NONitric oxide
NT-proBNPN-terminal pro-B-type natriuretic peptide
pCREBPhosphorylated cyclic AMP-response element DNA-binding protein
PCsPhenolic compounds
SBPSystolic blood pressure

References

  1. Magrone, T.; Russo, M.A.; Jirillo, E. Cocoa and Dark Chocolate Polyphenols: From Biology to Clinical Applications. Front. Immunol. 2017, 8, 677. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Centre for the Promotion of Imports from developing countries (CBI), What Is the Demand for Cocoa on the European Market? Available online: https://www.cbi.eu/market-information/cocoa/what-demand#:~:text=The%20average%20per%20capita%20chocolate,€42%20billion%20in%202022 (accessed on 9 May 2023).
  3. Meng, C.C.; Jalil, A.M.; Ismail, A. Phenolic and Theobromine Contents of Commercial Dark, Milk and White Chocolates on the Malaysian Market. Molecules 2009, 14, 200–209. [Google Scholar] [CrossRef] [Green Version]
  4. Miller, K.B.; Hurst, W.J.; Flannigan, N.; Ou, B.; Lee, C.Y.; Smith, N.; Stuart, D.A. Survey of Commercially Available Chocolate- and Cocoa-Containing Products in the United States. 2. Comparison of Flavan-3-ol Content with Nonfat Cocoa Solids, Total Polyphenols, and Percent Cacao. J. Agric. Food Chem. 2009, 57, 9169–9180. [Google Scholar] [CrossRef] [PubMed]
  5. Rana, A.; Samtiya, M.; Dhewa, T.; Mishra, V.; Aluko, R.E. Health benefits of polyphenols: A concise review. J. Food Biochem. 2022, 46, e14264. [Google Scholar] [CrossRef] [PubMed]
  6. Olivoto, T.; Nardino, M.; Carvalho, I.R.; Follmann, D.N.; Szareski, V.J.; Ferrari, M.; de Pelegrin, A.J.; de Souza, V.Q. Plant secondary metabolites and its dynamical systems of induction in response to environmental factors: A review. Afr. J. Agric. Res. 2017, 12, 71–84. [Google Scholar] [CrossRef] [Green Version]
  7. Klepacka, J.; Gujska, E.; Michalak, J. Phenolic Compounds as Cultivar- and Variety-distinguishing Factors in Some Plant Products. Plant Foods Hum. Nutr. 2011, 66, 64–69. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Ried, K.; Fakler, P.; Stocks, N.P. Effect of cocoa on blood pressure. Cochrane Database Syst. Rev. 2017, 4, Cd008893. [Google Scholar] [CrossRef]
  9. Razola-Díaz, M.D.; Aznar-Ramos, M.J.; Verardo, V.; Melgar-Locatelli, S.; Castilla-Ortega, E.; Rodríguez-Pérez, C. Exploring the Nutritional Composition and Bioactive Compounds in Different Cocoa Powders. Antioxidants 2023, 12, 716. [Google Scholar] [CrossRef] [PubMed]
  10. De Araujo, Q.R.; Gattward, J.N.; Almoosawi, S.; Silva, M.; Dantas, P.A.; De Araujo Júnior, Q.R. Cocoa and Human Health: From Head to Foot—A Review. Crit. Rev. Food Sci. Nutr. 2016, 56, 1–12. [Google Scholar] [CrossRef]
  11. Sorrenti, V.; Ali, S.; Mancin, L.; Davinelli, S.; Paoli, A.; Scapagnini, G. Cocoa Polyphenols and Gut Microbiota Interplay: Bioavailability, Prebiotic Effect, and Impact on Human Health. Nutrients 2020, 12, 1908. [Google Scholar] [CrossRef]
  12. Socci, V.; Tempesta, D.; Desideri, G.; De Gennaro, L.; Ferrara, M. Enhancing Human Cognition with Cocoa Flavonoids. Front. Nutr. 2017, 4, 19. [Google Scholar] [CrossRef] [Green Version]
  13. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the modification of the authorisation of a health claim related to cocoa flavanols and maintenance of normal endothelium- dependent vasodilation pursuant to Article 13(5) of Regulation (EC) No 1924/20061 following a request in accordance with Article 19 of Regulation (EC) No 1924/2006. EFSA J. 2014, 12, 3654. [Google Scholar]
  14. Hormaza, L.C.; Londoño, J.; Gil, A. Comparison of polyphenol, methylxanthines and antioxidant activity in Theobroma cacao beans from different cocoa-growing areas in Colombia. Food Res. Int. 2014, 60, 273–280. [Google Scholar] [CrossRef]
  15. Urbańska, B.; Kowalska, J. Comparison of the Total Polyphenol Content and Antioxidant Activity of Chocolate Obtained from Roasted and Unroasted Cocoa Beans from Different Regions of the World. Antioxidants 2019, 8, 283. [Google Scholar] [CrossRef] [Green Version]
  16. Oracz, J.; Nebesny, E.; Zyzelewicz, D.; Budryn, G.; Luzak, B. Bioavailability and metabolism of selected cocoa bioactive compounds: A comprehensive review. Crit. Rev. Food Sci. Nutr. 2020, 60, 1947–1985. [Google Scholar] [CrossRef]
  17. García-Merino, J.Á.; Moreno-Pérez, D.; de Lucas, B.; Montalvo-Lominchar, M.G.; Muñoz, E.; Sánchez, L.; Naclerio, F.; Herrera-Rocha, K.M.; Moreno-Jiménez, M.R.; Rocha-Guzmán, N.E.; et al. Chronic flavanol-rich cocoa powder supplementation reduces body fat mass in endurance athletes by modifying the follistatin/myostatin ratio and leptin levels. Food Funct. 2020, 11, 3441–3450. [Google Scholar] [CrossRef] [PubMed]
  18. Patel, R.K.; Brouner, J.; Allgrove, J.E.; Spendiff, O. The influence of different concentrations of flavanol chocolate bars under acute supplement conditions on exercise and performance. Eur. J. Appl. Physiol. 2020, 120, 2075–2082. [Google Scholar] [CrossRef] [PubMed]
  19. García-Merino, J.A.; de Lucas, B.; Herrera-Rocha, K.; Moreno-Pérez, D.; Montalvo-Lominchar, M.G.; Fernández-Romero, A.; Santiago, C.; Pérez-Ruiz, M.; Larrosa, M. Flavanol-Rich Cocoa Supplementation Inhibits Mitochondrial Biogenesis Triggered by Exercise. Antioxidants 2022, 11, 1522. [Google Scholar] [CrossRef]
  20. Wiswedel, I.; Hirsch, D.; Kropf, S.; Gruening, M.; Pfister, E.; Schewe, T.; Sies, H. Flavanol-rich cocoa drink lowers plasma F2-isoprostane concentrations in humans. Free. Radic. Biol. Med. 2004, 37, 411–421. [Google Scholar] [CrossRef]
  21. Zhu, Q.Y.; Schramm, D.D.; Gross, H.B.; Holt, R.R.; Kim, S.H.; Yamaguchi, T.; Kwik-Uribe, C.L.; Keen, C.L. Influence of cocoa flavanols and procyanidins on free radical-induced human erythrocyte hemolysis. Clin. Dev. Immunol. 2005, 12, 27–34. [Google Scholar] [CrossRef] [Green Version]
  22. Munguia, L.; Rubio-Gayosso, I.; Ramirez-Sanchez, I.; Ortiz, A.; Hidalgo, I.; Gonzalez, C.; Meaney, E.; Villarreal, F.; Najera, N.; Ceballos, G. High Flavonoid Cocoa Supplement Ameliorates Plasma Oxidative Stress and Inflammation Levels While Improving Mobility and Quality of Life in Older Subjects: A Double-Blind Randomized Clinical Trial. J. Gerontol. A Biol. Sci. Med. Sci. 2019, 74, 1620–1627. [Google Scholar] [CrossRef] [PubMed]
  23. Martínez-López, S.; Sarriá, B.; Sierra-Cinos, J.L.; Goya, L.; Mateos, R.; Bravo, L. Realistic intake of a flavanol-rich soluble cocoa product increases HDL-cholesterol without inducing anthropometric changes in healthy and moderately hypercholesterolemic subjects. Food Funct. 2014, 5, 364–374. [Google Scholar] [CrossRef]
  24. Grassi, D.; Socci, V.; Tempesta, D.; Ferri, C.; De Gennaro, L.; Desideri, G.; Ferrara, M. Flavanol-rich chocolate acutely improves arterial function and working memory performance counteracting the effects of sleep deprivation in healthy individuals. J. Hypertens. 2016, 34, 1298–1308. [Google Scholar] [CrossRef]
  25. Neukam, K.; Stahl, W.; Tronnier, H.; Sies, H.; Heinrich, U. Consumption of flavanol-rich cocoa acutely increases microcirculation in human skin. Eur. J. Nutr. 2007, 46, 53–56. [Google Scholar] [CrossRef] [PubMed]
  26. Heiss, C.; Kleinbongard, P.; Dejam, A.; Perré, S.; Schroeter, H.; Sies, H.; Kelm, M. Acute Consumption of Flavanol-Rich Cocoa and the Reversal of Endothelial Dysfunction in Smokers. J. Am. Coll. Cardiol. 2005, 46, 1276–1283. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Heiss, C.; Finis, D.; Kleinbongard, P.; Hoffmann, A.; Rassaf, T.; Kelm, M.; Sies, H. Sustained Increase in Flow-Mediated Dilation After Daily Intake of High-Flavanol Cocoa Drink Over 1 Week. J. Cardiovasc. Pharmacol. 2007, 49, 74–80. [Google Scholar] [CrossRef] [Green Version]
  28. Kim, K.; Brothers, R.M. Acute consumption of flavanol-rich cocoa beverage improves attenuated cutaneous microvascular function in healthy young African Americans. Microvasc. Res. 2020, 128, 103931. [Google Scholar] [CrossRef]
  29. Pearson, D.A.; Paglieroni, T.G.; Rein, D.; Wun, T.; Schramm, D.D.; Wang, J.F.; Holt, R.R.; Gosselin, R.; Schmitz, H.H.; Keen, C.L. The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function. Thromb. Res. 2002, 106, 191–197. [Google Scholar] [CrossRef]
  30. Engler, M.B.; Engler, M.M.; Chen, C.Y.; Malloy, M.J.; Browne, A.; Chiu, E.Y.; Kwak, H.-K.; Milbury, P.; Paul, S.M.; Blumberg, J.; et al. Flavonoid-Rich Dark Chocolate Improves Endothelial Function and Increases Plasma Epicatechin Concentrations in Healthy Adults. J. Am. Coll. Nutr. 2004, 23, 197–204. [Google Scholar] [CrossRef]
  31. Fisher, N.D.L.; Hollenberg, N.K. Aging and vascular responses to flavanol-rich cocoa. J. Hypertens. 2006, 24, 1575–1580. [Google Scholar] [CrossRef] [Green Version]
  32. Fisher, N.D.L.; Hughes, M.; Gerhard-Herman, M.; Hollenberg, N.K. Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. J. Hypertens. 2003, 21, 2281–2286. [Google Scholar] [CrossRef]
  33. Ried, K.; Frank, O.R.; Stocks, N.P. Dark chocolate or tomato extract for prehypertension: A randomised controlled trial. BMC Complement. Altern. Med. 2009, 9, 22. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Tsukamoto, H.; Suga, T.; Ishibashi, A.; Takenaka, S.; Tanaka, D.; Hirano, Y.; Hamaoka, T.; Goto, K.; Ebi, K.; Isaka, T.; et al. Flavanol-rich cocoa consumption enhances exercise-induced executive function improvements in humans. Nutrition 2018, 46, 90–96. [Google Scholar] [CrossRef]
  35. Lamport, D.J.; Pal, D.; Moutsiana, C.; Field, D.T.; Williams, C.M.; Spencer, J.P.; Butler, L.T. The effect of flavanol-rich cocoa on cerebral perfusion in healthy older adults during conscious resting state: A placebo controlled, crossover, acute trial. Psychopharmacology 2015, 232, 3227–3234. [Google Scholar] [CrossRef] [Green Version]
  36. Sorond, F.A.; Lipsitz, L.A.; Hollenberg, N.K.; Fisher, N.D. Cerebral blood flow response to flavanol-rich cocoa in healthy elderly humans. Neuropsychiatr. Dis. Treat. 2008, 4, 433–440. [Google Scholar] [CrossRef]
  37. Francis, S.T.; Head, K.; Morris, P.G.; Macdonald, I.A. The Effect of Flavanol-rich Cocoa on the fMRI Response to a Cognitive Task in Healthy Young People. J. Cardiovasc. Pharmacol. 2006, 47, S215–S220. [Google Scholar] [CrossRef] [PubMed]
  38. Neshatdoust, S.; Saunders, C.; Castle, S.M.; Vauzour, D.; Williams, C.; Butler, L.; Lovegrove, J.A.; Spencer, J.P. High-flavonoid intake induces cognitive improvements linked to changes in serum brain-derived neurotrophic factor: Two randomised, controlled trials. Nutr. Healthy Aging 2016, 4, 81–93. [Google Scholar] [CrossRef] [Green Version]
  39. Mastroiacovo, D.; Kwik-Uribe, C.; Grassi, D.; Necozione, S.; Raffaele, A.; Pistacchio, L.; Righetti, R.; Bocale, R.; Lechiara, M.C.; Marini, C.; et al. Cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects: The Cocoa, Cognition, and Aging (CoCoA) Study--a randomized controlled trial. Am. J. Clin. Nutr. 2015, 101, 538–548. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Field, D.T.; Williams, C.M.; Butler, L.T. Consumption of cocoa flavanols results in an acute improvement in visual and cognitive functions. Physiol. Behav. 2011, 103, 255–260. [Google Scholar] [CrossRef] [Green Version]
  41. Siedlecki, J.; Mohr, N.; Luft, N.; Schworm, B.; Keidel, L.; Priglinger, S.G. Effects of Flavanol-Rich Dark Chocolate on Visual Function and Retinal Perfusion Measured With Optical Coherence Tomography Angiography: A Randomized Clinical Trial. JAMA Ophthalmol. 2019, 137, 1373–1379. [Google Scholar] [CrossRef]
  42. Karabay, A.; Saija, J.D.; Field, D.T.; Akyürek, E.G. The acute effects of cocoa flavanols on temporal and spatial attention. Psychopharmacology 2018, 235, 1497–1511. [Google Scholar] [CrossRef] [Green Version]
  43. Tzounis, X.; Rodriguez-Mateos, A.; Vulevic, J.; Gibson, G.R.; Kwik-Uribe, C.; Spencer, J.P.E. Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. Am. J. Clin. Nutr. 2011, 93, 62–72. [Google Scholar] [CrossRef] [Green Version]
  44. Heinrich, U.; Neukam, K.; Tronnier, H.; Sies, H.; Stahl, W. Long-Term Ingestion of High Flavanol Cocoa Provides Photoprotection against UV-Induced Erythema and Improves Skin Condition in Women1. J. Nutr. 2006, 136, 1565–1569. [Google Scholar] [CrossRef] [Green Version]
  45. Mogollon, J.A.; Boivin, C.; Lemieux, S.; Blanchet, C.; Claveau, J.; Dodin, S. Chocolate flavanols and skin photoprotection: A parallel, double-blind, randomized clinical trial. Nutr. J. 2014, 13, 66. [Google Scholar] [CrossRef] [PubMed]
  46. Mogollon, J.A.; Bujold, E.; Lemieux, S.; Bourdages, M.; Blanchet, C.; Bazinet, L.; Couillard, C.; Noël, M.; Dodin, S. Blood pressure and endothelial function in healthy, pregnant women after acute and daily consumption of flavanol-rich chocolate: A pilot, randomized controlled trial. Nutr. J. 2013, 12, 41. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Rassaf, T.; Rammos, C.; Hendgen-Cotta, U.B.; Heiss, C.; Kleophas, W.; Dellanna, F.; Floege, J.; Hetzel, G.R.; Kelm, M. Vasculoprotective Effects of Dietary Cocoa Flavanols in Patients on Hemodialysis: A Double-Blind, Randomized, Placebo-Controlled Trial. Clin. J. Am. Soc. Nephrol. 2016, 11, 108–118. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Berry, N.M.; Davison, K.; Coates, A.M.; Buckley, J.D.; Howe, P.R. Impact of cocoa flavanol consumption on blood pressure responsiveness to exercise. Br. J. Nutr. 2010, 103, 1480–1484. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. West, S.G.; McIntyre, M.D.; Piotrowski, M.J.; Poupin, N.; Miller, D.L.; Preston, A.G.; Wagner, P.; Groves, L.F.; Skulas-Ray, A.C. Effects of dark chocolate and cocoa consumption on endothelial function and arterial stiffness in overweight adults. Br. J. Nutr. 2014, 111, 653–661. [Google Scholar] [CrossRef] [Green Version]
  50. Esser, D.; Mars, M.; Oosterink, E.; Stalmach, A.; Müller, M.; Afinan, L.A. Dark chocolate consumption improves leukocyte adhesion factors and vascular function in overweight men. FASEB J. 2014, 28, 1464–1473. [Google Scholar] [CrossRef] [PubMed]
  51. Simpson, E.J.; Mendis, B.; Dunlop, M.; Schroeter, H.; Kwik-Uribe, C.; Macdonald, I.A. Cocoa Flavanol Supplementation and the Effect on Insulin Resistance in Females Who Are Overweight or Obese: A Randomized, Placebo-Controlled Trial. Nutrients 2023, 15, 565. [Google Scholar] [CrossRef]
  52. Davison, K.; Coates, A.M.; Buckley, J.D.; Howe, P.R. Effect of cocoa flavanols and exercise on cardiometabolic risk factors in overweight and obese subjects. Int. J. Obes. 2008, 32, 1289–1296. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Balzer, J.; Rassaf, T.; Heiss, C.; Kleinbongard, P.; Lauer, T.; Merx, M.; Heussen, N.; Gross, H.B.; Keen, C.L.; Schroeter, H.; et al. Sustained Benefits in Vascular Function Through Flavanol-Containing Cocoa in Medicated Diabetic Patients: A Double-Masked, Randomized, Controlled Trial. J. Am. Coll. Cardiol. 2008, 51, 2141–2149. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Campia, U.; Panza, J.A. Flavanol-Rich Cocoa: A Promising New Dietary Intervention to Reduce Cardiovascular Risk in Type 2 Diabetes?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. J. Am. Coll. Cardiol. 2008, 51, 2150–2152. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. De Palma, R.; Sotto, I.; Wood, E.G.; Khan, N.Q.; Butler, J.; Johnston, A.; Rothman, M.T.; Corder, R. Cocoa flavanols reduce N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure. ESC Heart Fail. 2016, 3, 97–106. [Google Scholar] [CrossRef]
  56. Horn, P.; Amabile, N.; Angeli, F.S.; Sansone, R.; Stegemann, B.; Kelm, M.; Springer, M.L.; Yeghiazarians, Y.; Schroeter, H.; Heiss, C. Dietary flavanol intervention lowers the levels of endothelial microparticles in coronary artery disease patients. Br. J. Nutr. 2014, 111, 1245–1252. [Google Scholar] [CrossRef]
  57. Farouque, H.M.O.; Leung, M.; Hope, S.A.; Baldi, M.; Schechter, C.; Cameron, J.D.; Meredith, I.T. Acute and chronic effects of flavanol-rich cocoa on vascular function in subjects with coronary artery disease: A randomized double-blind placebo-controlled study. Clin. Sci. 2006, 111, 71–80. [Google Scholar] [CrossRef] [Green Version]
  58. Wang-Polagruto, J.F.; Villablanca, A.C.; Polagruto, J.A.; Lee, L.; Holt, R.R.; Schrader, H.R.; Ensunsa, J.L.; Steinberg, F.M.; Schmitz, H.H.; Keen, C.L. Chronic Consumption of Flavanol-rich Cocoa Improves Endothelial Function and Decreases Vascular Cell Adhesion Molecule in Hypercholesterolemic Postmenopausal Women. J. Cardiovasc. Pharmacol. 2006, 47, S206–S209. [Google Scholar] [CrossRef] [Green Version]
  59. Davison, K.; Berry, N.M.; Misan, G.; Coates, A.M.; Buckley, J.D.; Howe, P.R.C. Dose-related effects of flavanol-rich cocoa on blood pressure. J. Hum. Hypertens. 2010, 24, 568–576. [Google Scholar] [CrossRef]
  60. Muniyappa, R.; Hall, G.; Kolodziej, T.L.; Karne, R.J.; Crandon, S.K.; Quon, M.J. Cocoa consumption for 2 wk enhances insulin-mediated vasodilatation without improving blood pressure or insulin resistance in essential hypertension. Am. J. Clin. Nutr. 2008, 88, 1685–1696. [Google Scholar] [CrossRef] [Green Version]
  61. Rull, G.; Mohd-Zain, Z.N.; Shiel, J.; Lundberg, M.H.; Collier, D.J.; Johnston, A.; Warner, T.D.; Corder, R. Effects of high flavanol dark chocolate on cardiovascular function and platelet aggregation. Vasc. Pharmacol. 2015, 71, 70–78. [Google Scholar] [CrossRef] [Green Version]
  62. Coe, S.; Andreoli, D.; George, M.; Collett, J.; Reed, A.; Cossington, J.; Izadi, H.; Dixon, A.; Mansoubi, M.; Dawes, H. A feasibility study to determine whether the daily consumption of flavonoid-rich pure cocoa has the potential to reduce fatigue and fatigability in people with Parkinson’s (pwP). Clin. Nutr. ESPEN 2022, 48, 68–73. [Google Scholar] [CrossRef] [PubMed]
  63. Coe, S.; Jo, C.; Johnny, C.; Andrew, S.; Hooshang, I.; Martin, O.; Luke, D.; Maja, K.; Miriam, C.; Ana, C.; et al. A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2019, 90, 507. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Coe, S.; Axelsson, E.; Murphy, V.; Santos, M.; Collett, J.; Clegg, M.; Izadi, H.; Harrison, J.M.; Buckingham, E.; Dawes, H. Flavonoid rich dark cocoa may improve fatigue in people with multiple sclerosis, yet has no effect on glycaemic response: An exploratory trial. Clin. Nutr. ESPEN 2017, 21, 20–25. [Google Scholar] [CrossRef] [PubMed]
  65. Franco, R.; Oñatibia-Astibia, A.; Martínez-Pinilla, E. Health Benefits of Methylxanthines in Cacao and Chocolate. Nutrients 2013, 5, 4159–4173. [Google Scholar] [CrossRef] [Green Version]
  66. Martínez-Pinilla, E.; Oñatibia-Astibia, A.; Franco, R. The relevance of theobromine for the beneficial effects of cocoa consumption. Front. Pharmacol. 2015, 6, 30. [Google Scholar] [CrossRef] [Green Version]
  67. Katz, D.L.; Doughty, K.; Ali, A. Cocoa and chocolate in human health and disease. Antioxid. Redox Signal 2011, 15, 2779–2811. [Google Scholar] [CrossRef] [Green Version]
  68. Van Dam, R.M.; Hu, F.B.; Willett, W.C. Coffee, Caffeine, and Health. N. Engl. J. Med. 2020, 383, 369–378. [Google Scholar] [CrossRef]
  69. Melgar-Locatelli, S.; de Ceglia, M.; Mañas-Padilla, M.C.; Rodriguez-Pérez, C.; Castilla-Ortega, E.; Castro-Zavala, A.; Rivera, P. Nutrition and adult neurogenesis in the hippocampus: Does what you eat help you remember? Front. Neurosci. 2023, 17, 1147269. [Google Scholar] [CrossRef]
  70. Vázquez-Agell, M.; Urpi-Sarda, M.; Sacanella, E.; Camino-López, S.; Chiva-Blanch, G.; Llorente-Cortés, V.; Tobias, E.; Roura, E.; Andres-Lacueva, C.; Lamuela-Raventós, R.M.; et al. Cocoa consumption reduces NF-κB activation in peripheral blood mononuclear cells in humans. Nutr. Metab. Cardiovasc. Dis. 2013, 23, 257–263. [Google Scholar] [CrossRef]
  71. Andres-Lacueva, C.; Monagas, M.; Khan, N.; Izquierdo-Pulido, M.; Urpi-Sarda, M.; Permanyer, J.; Lamuela-Raventós, R.M. Flavanol and flavonol contents of cocoa powder products: Influence of the manufacturing process. J. Agric. Food Chem. 2008, 56, 3111–3117. [Google Scholar] [CrossRef]
  72. Urbańska, B.; Derewiaka, D.; Lenart, A.; Kowalska, J. Changes in the composition and content of polyphenols in chocolate resulting from pre-treatment method of cocoa beans and technological process. Eur. Food Res. Technol. 2019, 245, 2101–2112. [Google Scholar] [CrossRef] [Green Version]
  73. González-Barrio, R.; Nuñez-Gomez, V.; Cienfuegos-Jovellanos, E.; García-Alonso, F.J.; Periago-Castón, M.J. Improvement of the Flavanol Profile and the Antioxidant Capacity of Chocolate Using a Phenolic Rich Cocoa Powder. Foods 2020, 9, 189. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Kelm, M.A.; Johnson, J.C.; Robbins, R.J.; Hammerstone, J.F.; Schmitz, H.H. High-performance liquid chromatography separation and purification of cacao (Theobroma cacao L.) procyanidins according to degree of polymerization using a diol stationary phase. J. Agric. Food Chem. 2006, 54, 1571–1576. [Google Scholar] [CrossRef] [PubMed]
  75. Zhong, J.-L.; Muhammad, N.; Gu, Y.-C.; Yan, W.-D. A simple and efficient method for enrichment of cocoa polyphenols from cocoa bean husks with macroporous resins following a scale-up separation. J. Food Eng. 2019, 243, 82–88. [Google Scholar] [CrossRef]
Figure 1. Main phenolic compounds of cocoa.
Figure 1. Main phenolic compounds of cocoa.
Antioxidants 12 01376 g001
Table 1. Effects on exercise performance and oxidative stress in healthy subjects.
Table 1. Effects on exercise performance and oxidative stress in healthy subjects.
DoseDurationSubjectsEffectsRef
HF cocoa (425 mg) or
maltodextrin
weeks44 male endurance athletes
34.5 ± 7.5 years
↑* plasma follistatin
↓* body fat
↓* plasma leptin
[17]
HF (1060 mg), MF (746 mg), LF (406 mg), or control (CON) (88 mg) chocolate bar
Cross-over
Single dose15 healthy subjects (10 males, 5 females)
30 ± 7 years
No effects on oxygen consumption respiratory exchange ratio or (HR)[18]
HF (425 mg) cocoa or
maltodextrin
10 weeks56 male endurance athletes
35.8 ± 8.1 years
↓** oxidative stress
No effect on aerobic capacity or exercise performance
[19]
HF (187 mg) or LF (14 mg) cocoa drink
Cross-over
Single dose20 healthy males
20–40 years
↓** oxidative stress[20]
HF (25 mg/kg body weigh), MF (18.78 mg/kg) or LF (12.5 mg/kg) cocoa drink
Cross-over
Single dose8 healthy male subjects
26 ± 2 years
↓* susceptibility to free radical-induced haemolysis (all doses)[21]
↑ increase. ↓ decrease. * Significantly different from baseline. ** Significantly different from control. HF: high-flavanol; MF: medium-flavanol; LF: low-flavanol; HR: heart rate.
Table 3. Effects on brain-related factors and cognitive function in healthy subjects.
Table 3. Effects on brain-related factors and cognitive function in healthy subjects.
DoseDurationSubjectsEffectsRef
HF (494 mg) or LF (23 mg) cocoa drink
Cross-over
Single dose18 healthy older adults (8 males, 10 females)
61 years
↑** cerebral blood flow[35]
HF (900 mg/d) or LF (36 mg/d) cocoa drink1 weeks34 healthy elderly subjects (16 males, 18 females)
72 ± 6 years
↑* blood flow velocity (MFV) in the middle cerebral artery [36]
HF (172 mg) or LF (13 mg) cocoa drink5 days16 healthy young females
18–30 y
↑* cerebral blood flow[37]
HF (494 mg) or LF (23 mg) cocoa drink12 weeks40 healthy older subjects (22 males, 18 females)
68.3 ± 3 years
↑** serum BDNF levels[38]
HF (990 mg), MF (520 mg) or LF (45 mg) cocoa drink8 weeks90 healthy elderly subjects (37 males, 53 females)
69.6 years
a cognitive function
a insulin resistance, BP, and lipid peroxidation
[39]
HF (720 mg) dark chocolate or white chocolate
Cross-over
Single dose30 healthy subjects (8 males, 22 females)
18–25 years
↑** visual function
↑** cognitive function
[40]
HF (400 mg) dark chocolate or milk chocolate (5 mg)
Cross-over
Single dose22 healthy subjects (9 males, 13 females)
27.3 ± 11.1 years
No effects on retinal perfusion or subjective visual function[41]
HF (747 mg), MF (520 mg) or LF (374 mg) cocoa drinkSingle dose48 healthy subjects (24 males, 24 females)
22.2 years
↑* spatial attention
No effects on temporal attention
[42]
↑ increase. ↓ decrease. * Significantly different from baseline. ** Significantly different from control. a Significantly different in the high- and middle-cocoa groups with respect to the low-cocoa group. HF: high-flavanol; MF: medium-flavanol; LF: low-flavanol; BDNF: brain-derived neurotrophic factor; BP: blood pressure.
Table 4. Other effects in healthy subjects.
Table 4. Other effects in healthy subjects.
DoseDurationSubjectsEffectsRef
HF (494 mg) cocoa drink or placebo (29 mg)
Cross-over
4 weeks22 healthy subjects (12 males, 10 females)
30.2 ± 11.8 years
↑** Bifidobacterial and lactobacilli populations
↓** Clostridia population
↓** Plasma triacylglycerol and C-reactive protein
[43]
HF (326 mg/d) or LF (27 mg/d) cocoa drink6 weeks24 healthy women
18–65 years
↓** UV-induced erythema
↑** blood flow of cutaneous and subcutaneous tissues, skin density and skin hydration
[44]
HF (200 mg) or LF (<30 mg) chocolate12 weeks74 healthy women
39.5 ± 13.1 years
↑** net skin elasticity
No effects on UV-induced erythema
[45]
HF (400 mg) or LF (<60 mg) chocolate12 weeks44 healthy pregnant women
29.2 ± 3.4 years
↑** Plasma levels of theobromine
No effects on FMD or BP
[46]
↑ increase. ↓ decrease. ** Significantly different from control. HF: high-flavanol; LF: low-flavanol; UV: ultraviolet; FMD: flow-mediated dilatation; BP: blood pressure.
Table 5. Effects in subjects with disease.
Table 5. Effects in subjects with disease.
DoseDurationSubjectsEffectsRef
HF (900 mg) cocoa drink or non-containing placebo4 weeks52 subjects with end stage renal disease (38 males, 14 females)
65.5 ± 14 years
↑** FMD
↓** DBP
↑** heart rate
[47]
HF (701 mg) or LF (22 mg) cocoa drink
Cross-over
Single dose21 subjects with overweight or obesity (13 males, 8 females
54.9 ± 2.2 years
↓** Exercise-induced increases in BP
↑** FMD
[48]
HF (814 mg) or LF (3 mg) dark chocolate and cocoa drink
Cross-over
4 weeks30 subjects with overweight (15 males, 15 females)
51.7 ± 1.2 years
↑** basal diameter and peak diameter of the brachial artery
↑** basal blood flow volume
a AIX
No effects on fasting blood measures
[49]
HF (1078 mg) or LF (259 mg) chocolate
Cross-over
4 weeks44 men with overweight
63 ± 5 years
↑* FMD
↓* AIX
↓* leukocyte cell count and adhesion
[50]
HF (1218 mg/d) or LF (26 mg/d) cocoa drink4 weeks32 females with overweight or obesity
33.4 ± 10.2 years
No effects on HOMA-IR or insulin-stimulated glucose disposal[51]
HF (902 mg) or LF (36 mg) cocoa drink12 weeks23 subjects with overweight or obesity (7 males, 16 females)
44.9 ± 4.4 years
↑** FMD
↓** insulin resistance
↓** DBP and mean arterial BP
[52]
HF (963 mg/d) or LF (75 mg/d) cocoa drink4 weeks44 subjects with type II diabetes
50–80 years
↑** plasma flavanol metabolite levels
↑** FMD
[54]
HF (963 mg/d) or LF (75 mg/d) cocoa drink
Cross-over
4 weeks51 subjects with type II diabetes (20 males, 31 females)
63.8± 8.5 years
↑* FMD[53]
HF (1064 mg) or LF (88 mg) dark chocolate4 weeks24 subjects with chronic heart failure (20 males, 4 females)
70 ± 10 years
↓** NT-proBNP
↓** DBP
[55]
HF (750 mg) or LF (18 mg) cocoa drink
Cross-over
4 weeks16 subjects with coronary artery disease (13 males, 3 females)
64 ± 3 years
↓** levels of endothelial microparticles
↑** endothelial function
[56]
HF (444 mg/d) chocolate bar and cocoa drink or placebo (16.9 mg/d)6 weeks40 subjects with coronary artery disease (30 males, 10 females)
61 ± 8 years
No effects on brachial artery FMD or systemic arterial compliance
No effects on forearm blood flow
[57]
HF (446 mg) or LF (43 mg) cocoa drink6 weeks32 postmenopausal hypercholesterolemic women
56.6 ± 2.0 years
↓** sVCAM-1
↑** HDL
b SBP and DBP
[58]
HF (712–1052 mg), MF (372 mg) or LF (33 mg) cocoa drinkSingle dose32 men and 20 postmenopausal women with untreated mild hypertension
56.6 ± 11.1 years
↓** SBP, DBP and mean arterial BP[59]
HF (902 mg) cocoa drink or placebo drink (28 mg)
Cross-over
2 weeks20 subjects with hypertension (8 males, 12 females)
51.0 ± 1.5 years
↑** Insulin-stimulated changes in brachial artery diameter
No effects on BP or insulin resistance
[60]
HF (1064 mg) or LF (88 mg) dark chocolate
Cross-over
6 weeks32 men with hypertension
55.4 ± 1.5 years
↓** HR increase[61]
200 mL HF (194 mg) or LF (18.36 mg) cocoa drink1 week30 subjects with Parkinson (18 males, 12 females)
64.2 ± 11.6 years
↓ fatigability *[62]
HF (194 mg) or LF (18.36 mg) cocoa drink
Crossover
8 weeks40 subjects with multiple sclerosis (10 males, 30 females)
43.5 ± 9.5 years
↓ fatigability *[63]
HF (350 mg) or LF (120 mg) cocoa drink
Crossover
Single dose12 subjects with multiple sclerosis (2 males, 10 females)
54 ± 10.56 years
↓ self-reported fatigue
↓ activity during sleeping
↑ physical activity
↓ glycaemic response
No effect on fatigability measures
[64]
↑ increase. ↓ decrease. * Significantly different from baseline. ** Significantly different from control. a Significantly different only in women. b Significantly different in the low-cocoa group respect baseline. HF: high-flavanol; MF: medium-flavanol; LF: low-flavanol; FMD: flow-mediated dilatation; DBP: diastolic blood pressure; BP: blood pressure; AIX: augmentation index; NT-proBNP: N-terminal pro-B-type natriuretic peptide; SBP: systolic blood pressure; HR: heart rate.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Palma-Morales, M.; Melgar-Locatelli, S.; Castilla-Ortega, E.; Rodríguez-Pérez, C. How Healthy Is It to Fortify Cocoa-Based Products with Cocoa Flavanols? A Comprehensive Review. Antioxidants 2023, 12, 1376. https://doi.org/10.3390/antiox12071376

AMA Style

Palma-Morales M, Melgar-Locatelli S, Castilla-Ortega E, Rodríguez-Pérez C. How Healthy Is It to Fortify Cocoa-Based Products with Cocoa Flavanols? A Comprehensive Review. Antioxidants. 2023; 12(7):1376. https://doi.org/10.3390/antiox12071376

Chicago/Turabian Style

Palma-Morales, Marta, Sonia Melgar-Locatelli, Estela Castilla-Ortega, and Celia Rodríguez-Pérez. 2023. "How Healthy Is It to Fortify Cocoa-Based Products with Cocoa Flavanols? A Comprehensive Review" Antioxidants 12, no. 7: 1376. https://doi.org/10.3390/antiox12071376

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop